Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALDORIL 25 vs AMTURNIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.
AMTURNIDE is a combination of amiloride, a potassium-sparing diuretic that inhibits sodium reabsorption in the distal convoluted tubule and collecting duct, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium chloride reabsorption in the distal convoluted tubule. The combination produces additive diuretic and antihypertensive effects with reduced potassium loss.
Hypertension
Hypertension,Edema due to congestive heart failure,Edema due to hepatic cirrhosis,Edema due to nephrotic syndrome,Edema due to corticosteroid or estrogen therapy
Oral: 1 tablet (hydrochlorothiazide 25 mg/methyldopa 250 mg) twice daily; increase as needed to max 2 tablets twice daily.
10 mg to 20 mg orally once daily, with or without food.
7-16 hours (terminal). In renal impairment, half-life may exceed 24 hours, requiring dose adjustment.
Terminal elimination half-life is 12 hours (range 10–14 hours); steady-state achieved within 2–3 days.
Methyldopa is metabolized primarily via hepatic conjugation and renal excretion; hydrochlorothiazide is not significantly metabolized and is excreted unchanged in urine.
Amiloride is not metabolized and is excreted unchanged in the urine. Hydrochlorothiazide is not extensively metabolized; the majority is excreted unchanged in the urine via renal tubular secretion.
Renal: ~85% unchanged. Biliary/fecal: ~15% as metabolites.
Primarily renal excretion as unchanged drug (70%) and glucuronide conjugate (15%); biliary/fecal elimination accounts for 10%.
Methyldopa: less than 10% bound to plasma proteins. Hydrochlorothiazide: ~70% bound to plasma proteins (primarily albumin).
98% bound to albumin and alpha-1-acid glycoprotein.
Methyldopa: 0.3-0.6 L/kg (distributes widely, including CNS). Hydrochlorothiazide: 0.8-1.5 L/kg (distributes into extracellular fluid).
Vd = 0.15–0.25 L/kg; indicates primarily extracellular distribution.
Methyldopa: oral bioavailability ~25% (first-pass metabolism). Hydrochlorothiazide: oral bioavailability ~60-80%.
Oral: 40–50% due to first-pass metabolism.
GFR 30-50 m L/min: use with caution, reduce dose. GFR <30 m L/min: not recommended.
e GFR ≥30 m L/min/1.73 m²: no adjustment. e GFR 15-29 m L/min/1.73 m²: reduce dose to 10 mg once daily. e GFR <15 m L/min/1.73 m² or dialysis: not recommended.
Child-Pugh A: no adjustment; Child-Pugh B or C: contraindicated due to methyldopa hepatotoxicity risk.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose to 10 mg once daily. Child-Pugh C: not recommended.
Not established; avoid use in children.
Safety and efficacy not established; no recommended dose.
Start at lowest dose (1 tablet daily); monitor for orthostatic hypotension, sedation, and electrolyte imbalance.
No specific dose adjustment required, but monitor renal function closely due to age-related decline.
None
No FDA boxed warning.
May cause sedation, depression, positive direct Coombs test, hemolytic anemia, hepatotoxicity, fluid/electrolyte imbalance, and sensitivity reactions; monitor liver function, CBC, and electrolytes.
Hyperkalemia: Risk is increased in patients with renal impairment, diabetes, or elderly. Monitor serum potassium levels.,Hypersensitivity reactions: May occur with sulfonamide derivatives (hydrochlorothiazide).,Acute angle-closure glaucoma: Has been reported with sulfonamide derivatives.,Electrolyte imbalances: Including hyponatremia, hypochloremia, hypomagnesemia, and hypokalemia.,Renal impairment: Use with caution; may precipitate azotemia.,Hepatic impairment: Use with caution; may precipitate hepatic encephalopathy.,Diabetes: Thiazides may impair glucose tolerance.,Gout: Thiazides may increase serum uric acid levels.,SLE exacerbation: Thiazides may exacerbate systemic lupus erythematosus.
Hypersensitivity to methyldopa, hydrochlorothiazide, or sulfonamides; active hepatic disease; anuria; history of methyldopa-induced liver disorders.
Anuria,Acute or chronic renal insufficiency,Severe renal impairment (e GFR <30 m L/min),Hyperkalemia (serum potassium >5.5 m Eq/L),Hypersensitivity to amiloride, hydrochlorothiazide, or sulfonamide-derived drugs,Concomitant use with potassium-sparing diuretics, potassium supplements, or other drugs that increase potassium (e.g., ACE inhibitors, ARBs)
Avoid high-sodium foods to optimize antihypertensive effect. Limit alcohol intake. Do not consume large amounts of potassium-rich foods (e.g., bananas, oranges, spinach) unless advised by a healthcare provider, as hydrochlorothiazide can alter potassium levels.
Administration with food decreases absorption and may reduce efficacy. Take at least 30 minutes before a meal. No specific food-drug interactions reported.
First trimester: Limited human data, but animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Associated with fetal hypotension, oligohydramnios, and renal dysfunction due to methyldopa component. Hydrochlorothiazide may cause fetal electrolyte imbalances.
FDA Pregnancy Category C. In animal studies, amturnide (finerenone) caused embryofetal toxicity (reduced fetal body weight, delayed ossification, and increased resorptions) at maternal toxic doses. There are no adequate human studies. Risk cannot be ruled out; use only if potential benefit justifies potential risk. First trimester: unknown risk. Second/third trimester: potential for fetal renal effects due to mineralocorticoid receptor blockade.
Methyldopa is excreted in breast milk with M/P ratio of approximately 0.2-0.5; hydrochlorothiazide M/P ratio ~0.5-0.6. Considered compatible with breastfeeding by AAP, but monitor infant for hypotension and electrolyte disturbances.
No data on presence in human milk. Finerenone and its metabolites are excreted in rat milk. M/P ratio not determined in humans. Due to potential for serious adverse reactions in nursing infants (e.g., hyperkalemia, hypotension), breastfeeding is not recommended during therapy.
No standard dose adjustment required, but increased plasma volume in pregnancy may necessitate higher doses of methyldopa. Monitor clinical response and adjust accordingly.
No specific dose adjustments established. Pharmacokinetics may be altered due to increased volume of distribution and renal plasma flow; however, no data exist. Use lowest effective dose if essential. Monitor for hyperkalemia and hypotension, which may require dose reduction or discontinuation.
ALDORIL 25 is a fixed-dose combination of methyldopa (250 mg) and hydrochlorothiazide (25 mg). Monitor for hypotension, especially during initial therapy or with volume depletion. Methyldopa may cause a positive direct Coombs test and hemolytic anemia; discontinue if anemia develops. Hydrochlorothiazide can cause electrolyte imbalances, hyperglycemia, and hyperuricemia. Avoid use in patients with pheochromocytoma or active liver disease.
AMTURNIDE is a first-in-class guanylate cyclase-C receptor agonist for irritable bowel syndrome with constipation (IBS-C). It increases intestinal fluid secretion and transit without significant systemic absorption. Onset of action may occur within 24 hours, but full response may take 2-4 weeks. Avoid in patients with known or suspected mechanical gastrointestinal obstruction. Dose adjustment not required for renal or hepatic impairment.
Take this medication exactly as prescribed, usually once or twice daily.,Rise slowly from sitting or lying to prevent dizziness from low blood pressure.,Avoid alcohol, which can increase dizziness and drowsiness.,Report any signs of infection, unusual tiredness, or yellowing of skin/eyes.,Use sun protection as hydrochlorothiazide may increase sun sensitivity.,Do not use potassium supplements or salt substitutes without consulting your doctor.
Take once daily on an empty stomach at least 30 minutes before the first meal of the day.,Do not crush or chew the capsule; swallow whole with water.,Common side effects include diarrhea, abdominal pain, and flatulence; diarrhea is most frequent.,Seek medical attention if you experience severe or bloody diarrhea.,Notify your doctor if you are pregnant, breastfeeding, or have a history of bowel obstruction.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALDORIL 25 vs AMTURNIDE, answered by our medical review team.
ALDORIL 25 is a Antihypertensive Combination that works by Combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.. AMTURNIDE is a Antihypertensive Combination that works by AMTURNIDE is a combination of amiloride, a potassium-sparing diuretic that inhibits sodium reabsorption in the distal convoluted tubule and collecting duct, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium chloride reabsorption in the distal convoluted tubule. The combination produces additive diuretic and antihypertensive effects with reduced potassium loss.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALDORIL 25 and AMTURNIDE depend on the specific clinical indication. These are both Antihypertensive Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALDORIL 25 is: Oral: 1 tablet (hydrochlorothiazide 25 mg/methyldopa 250 mg) twice daily; increase as needed to max 2 tablets twice daily.. The standard adult dose of AMTURNIDE is: 10 mg to 20 mg orally once daily, with or without food.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALDORIL 25 and AMTURNIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALDORIL 25 is classified as Category C. First trimester: Limited human data, but animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Associated with fetal hypotension, oligohydramnios. AMTURNIDE is classified as Category C. FDA Pregnancy Category C. In animal studies, amturnide (finerenone) caused embryofetal toxicity (reduced fetal body weight, delayed ossification, and increased resorptions) at mate. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.